Immunofluorescence Can Assess the Efficacy of mTOR Pathway Therapeutic Agent Everolimus in Breast Cancer Models

Scientific Reports - United Kingdom
doi 10.1038/s41598-019-45319-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Vertical Inhibition of the PI3K/Akt/mTOR Pathway Is Synergistic in Breast Cancer

Oncogenesis
Cancer ResearchMolecular Biology
2017English

Apoptosis Induced by PGC-1β in Breast Cancer Cells Is Mediated by the mTOR Pathway

Oncology Reports
MedicineCancer ResearchOncology
2013English

Continuous Docetaxel Chemotherapy Improves Therapeutic Efficacy in Murine Models of Ovarian Cancer

Molecular Cancer Therapeutics
Cancer ResearchOncology
2010English

Correlation Between Activation of PI3K/AKT/mTOR Pathway and Prognosis of Breast Cancer in Chinese Women

PLoS ONE
Multidisciplinary
2015English

Therapeutic MUC1-Based Cancer Vaccine Expressed in Flagella-Efficacy in an Aggressive Model of Breast Cancer

World Journal of Vaccines
2012English

Are We Missing the mTOR Target in Breast Cancer?

Breast Cancer Research and Treatment
Cancer ResearchOncology
2010English

Everolimus Restrains the Paracrine Pro-Osteoclast Activity of Breast Cancer Cells

BMC Cancer
Cancer ResearchOncologyGenetics
2015English

Berberine Reverses Doxorubicin Resistance by Inhibiting Autophagy Through the PTEN/Akt/mTOR Signaling Pathway in Breast Cancer

OncoTargets and Therapy
OncologyPharmacology
2020English

Gene Expression Profiling of Response to mTOR Inhibitor Everolimus in Pre-Operatively Treated Post-Menopausal Women With Oestrogen Receptor-Positive Breast Cancer

Breast Cancer Research and Treatment
Cancer ResearchOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy